Elan Corp. to lay off 230 employees
DUBLIN, Ireland Irish biotech company Elan Corp. will lay off about 230 employees, half of them in the United States, the company announced Wednesday.
Most of the positions to be eliminated are in research, clinical development, biopharmaceutical development, corporate support and administrative services. The company said the layoffs and other adjustments will save about $50 million in a full year, some of which the company will invest in the development of its pipeline.
“As we continue to advance the company, we remain committed to the precise and specific investment in new talent, new technologies and novel therapeutic opportunities in the neuroscience field,” Elan CEO Kelly Martin stated. “This will further strengthen our core business areas that bring the greatest potential value to patients and shareholders, and enable us to invest in our most valuable programs within the biopharmaceuticals and Elan Drug Technologies businesses.”
Take Care Health Systems opens New Orleans clinic
CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened a new clinic in the New Orleans area.
The new location makes four Take Care Clinics in that market. In total, the clinic operator has 332 clinics in 35 markets throughout 19 states.
Eli Lilly’s chemotherapy drug granted tentative approval by FDA
ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to a generic version of Eli Lilly & Co.’s chemotherapy drug Gemzar, agency records show.
The FDA issued the tentative approval Monday to Hospira’s 2 g gemcitabine hydrochloride injection. The drug is used to treat non-small cell lung cancer, pancreatic cancer, ovarian, breast cancer and others.
Gemzar had worldwide sales of $1.6 billion in 2007, according to Lilly financial data. According to the FDA Orange Book, the drug will lose patent protection next year.